Global Granisetron Market Size, Share, and COVID-19 Impact Analysis, By Product Type (Transdermal, Injection, and Oral), By Applications (Postoperative Nausea, Chemotherapy-Induced Nausea, and Radiation Induced Nausea), By Distribution Channel (Retail Pharmacies, Online Pharmacies, and Hospital Pharmacies), and By Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa), Analysis and Forecast 2023 - 2033

Global Granisetron Market Insights Forecasts to 2033

• The Global Granisetron Market Size was estimated at USD 6.94 billion in 2023
• The Market Size is expected to grow at a CAGR of around 6.52% from 2023 to 2033
• The Worldwide Granisetron Market Size is expected to reach USD 13.05 billion by 2033
• Asia Pacific is predicted to Grow at the Fastest CAGR throughout the projection period

The Global Granisetron Market Size is anticipated to exceed USD 13.05 billion by 2033, growing at a CAGR of 6.52% from 2023 to 2033.

Market Overview

The granisetron market is introduced as the development, production, and distribution of the granisetron medications, used to prevent and treat nausea and vomiting derived from chemotherapy, radiation therapy, and post-operative conditions. Granisetron is classified under the anti-emetic class of drugs as a 5-hydroxytryptamine (5-HT3) receptor antagonist. The marketed products of the granisetron are GraniCare, GRANITERO, Granistorm, etc.

The rising cases of the post-cancer treatment escalates the need for the granisetron medications, which drives the market growth. For instance, the data provided by the National Cancer Institute under the United States government states that chemotherapy-induced nausea and vomiting (CINV) is a common adverse event experienced by cancer patients, causing significant morbidity and negatively impacting their quality of life. The incidence of acute N&V varies between 30% and 90% with moderate- or high-risk chemotherapy. However, recent advancements in antiemetic medications and combinations have significantly reduced the incidence and severity of this complication, making it a less feared complication.

The rising global incidence of cancer is driving the growth of the granisetron market. Since more cancer cases are being identified early, owing to technological and medical diagnostic advancements, more people are receiving chemotherapy. The need for supportive care drugs like granisetron, which controls chemotherapy-related nausea and vomiting, has surged as an outcome. The market is expanding as more individuals become aware that antiemetic treatments can enhance the quality of life for cancer patients. Investing substantially in the development of sophisticated formulations and drug delivery systems for granisetron, the pharmaceutical industry is investigating novel approaches such as transdermal patches and long-acting injectable formulations. These technological developments give producers a competitive edge and expand the range of granisetron applications.

Report Coverage

This research report categorizes the global granisetron market based on various segments and regions, forecasts revenue growth, and analyzes trends in each submarket. The report analyzes the key growth drivers, opportunities, and challenges influencing the global granisetron market. Recent market developments and competitive strategies such as expansion, product launch, and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyzes their core competencies in each sub-segment of the global granisetron market.

Driving Factors:

Rising cases of nausea and vomiting in patients with malignant tumors (cancer):

The increase in nausea and vomiting caused by cancer therapies, especially chemotherapy, is driving growth in the granisetron market. The quality of life of patients may be significantly impacted by these side effects. Granisetron, a serotonin 5-HT3 receptor antagonist, is being utilized extensively to treat nausea and vomiting triggered by chemotherapy. Strong antiemetic therapies are anticipated to grow increasingly more in demand as medical professionals emphasize patient-centered care before effectively managing side effects. The market is anticipated to grow more rapidly as a result of enhanced screening procedures, increased funding for cancer research, and improved treatment paths.

Innovations in the granisetron formulations:

Granisetron fast-dissolving tablets have been invented by researchers; these pills dissolve rapidly in the mouth and increase patient compliance, particularly for those experiencing trouble swallowing. Granisetron formulation has been optimized to increase its bioavailability by its incorporation of sophisticated excipients and direct compression. In an attempt to meet the needs of diverse patients, granisetron is currently available in a variety of forms, such as intravenous injections, sublingual formulations, and oral tablets, and to manage nausea and vomiting caused on by chemotherapy, radiation, and surgery, new inhalation formulations are currently being developed for pulmonary delivery. Additionally, granisetron has been added to medicated chewing gum to provide immediate relief.

Restraining Factors

The availability of alternative antiemetic medications, stringent regulatory guidelines, side effects obtained from the consumption of the granisetron, growing trend and use of the ayurveda and homemade solutions, and lack of awareness in low-middle-income countries may limit the market growth.

Market Segmentation

The market share is classified into product type, applications, and distribution channel.

• The oral segment dominated the global granisetron market in 2023 and is anticipated to grow at a significant CAGR throughout the forecast period.

Based on the product type, the global granisetron market is categorized into transdermal, injection, and oral. Among these, the oral segment dominated the global granisetron market in 2023 and is anticipated to grow at a significant CAGR throughout the forecast period. The segment growth is attributed to patient compliance, accurate dosing, availability in controlled drug delivery, ease of administration, non-invasiveness, greater physical and chemical stability, ease of handling, suitability for the geriatric and pediatric dosage form, cost-effectiveness, and rapid onset of action.

• The chemotherapy-induced nausea segment accounted for the largest share in 2023 and is expected to grow at a significant CAGR throughout the projected timeframe.

Based on the applications, the global granisetron market is categorized into postoperative nausea, chemotherapy-induced nausea, and radiation-induced nausea. Among these, the chemotherapy-induced nausea segment accounted for the largest share in 2023 and is expected to grow at a significant CAGR throughout the projected timeframe. The segment's growth is attributed to the increasing prevalence of cancer, the rising proportion of cancer treatments for cancer, the increase in the intake of emetogenic drugs, and growing chemotherapy in healthcare sectors.

• The hospital pharmacies held the largest share in 2023 and is predicted to grow at a remarkable CAGR throughout the projected timeframe.

Based on the distribution channel, the global granisetron market is categorized as retail pharmacies, online pharmacies, and hospital pharmacies. Among these, the hospital pharmacies held the largest share in 2023 and is predicted to grow at a remarkable CAGR throughout the projected timeframe. The segment expansion is ascribed to higher dispensing rates of granisetron, increasing prevalence of the cancerous diseases, and acidity complications leading to a rise in the purchasing of anti-emetic medications such as granisetron.

Regional Segment Analysis of the Global Granisetron Market

• North America (U.S., Canada, Mexico) 
• Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
• Asia-Pacific (China, Japan, India, Rest of APAC)
• South America (Brazil and the Rest of South America) 
• The Middle East and Africa (UAE, South Africa, Rest of MEA)

North America is anticipated to hold the largest share of the global granisetron market over the predicted timeframe.

North America is anticipated to hold the largest share of the global granisetron market over the predicted timeframe. The market for granisetron is dominated by North America because of its high cancer prevalence and well-established healthcare system. The market for granisetron in North America is expanding rapidly, owing in addition to the existence of large pharmaceutical companies and a strong emphasis on research and development. High patient knowledge of antiemetic treatments and advantageous reimbursement policies additionally contribute to the market's growth in this area.

Asia Pacific is anticipated to grow at the fastest CAGR throughout the projected timeframe. The rising prevalence of cancer and other chronic illnesses, along with advancements in healthcare infrastructure, are fostering a learning environment that is favorable for market expansion. The demand for granisetron is anticipated to increase in the upcoming years, owing to the fast urbanization and rising healthcare costs in emerging economies like China and India. Granisetron use in the Asia Pacific area is also being fueled by rising awareness regarding supportive medicines and cancer care.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the global granisetron market, along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• Sun Pharmaceutical Industries, Ltd.
• Lupin Limited
• Sandoz International GmbH
• Hikma Pharmaceuticals PLC
• Mylan N.V
• Sanofi S.A
• Torrent Pharmaceuticals
• GlaxoSmithKline
• Cipla Limited
• Pfizer
• Aurobindo Pharma Limited
• Amneal Pharmaceuticals
• Teva Pharmaceuticals Industries Ltd.
• Others

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Recent Developments

• In January 2022, Cumberland Pharmaceuticals received the FDA approval for oncology-supportive care medicine SANCUSO® (granisetron transdermal patch), the first and only prescription patch for preventing nausea and vomiting in patients receiving certain types of chemotherapy treatment. The active drug, granisetron, dissolves in the adhesive and is released into the patient's bloodstream over several days, working continuously to prevent chemotherapy-induced nausea and vomiting (CINV). Alternative oral treatments must be taken multiple times to deliver the same therapeutic doses.

Market Segment

This study forecasts revenue at global, regional, and country levels from 2023 to 2033. Spherical Insights has segmented the global granisetron market based on the below-mentioned segments:

Global Granisetron Market, By Product Type

• Transdermal
• Injection
• Oral

Global Granisetron Market, By Applications

• Postoperative Nausea
• Chemotherapy-Induced Nausea
• Radiation-Induced Induced Nausea

Global Granisetron Market, By Distribution Channel

• Retail Pharmacies
• Online Pharmacies
• Hospital Pharmacies

Global Granisetron Market, By Regional

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • Qatar
  • South Africa
  • Rest of the Middle East & Africa